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Introduction
Approximately one-third of dermatology patients are estimated to have underlying psychiatric comorbidity, and psychiatric illness may either be the cause or the consequence of dermatologic disease.
1,2 Individuals with body dysmorphic disorder (BDD) are highly distressed and impaired owing to defects they perceive in their physical appearance that are not observable to others; if a minor physical anomaly is present, the individual's concern is markedly excessive. 3 Most individuals have concerns involving the face or head, usually the skin (e.g. perceived acne, scars, wrinkles, or paleness), hair (e.g. thinning hair or excessive body or facial hair), and nose. 4, 5 BDD sufferers engage in excessive grooming, skin picking, mirror checking, and camouflaging of their appearance, with the aim of correcting, hiding, or distracting others from perceived defective parts of the body. Focusing on unattractive parts of the body, rumination, mental rituals, or other mental acts are also often reported. 6, 7 These preoccupations are generally time-consuming, occurring on average 3-8 hours a day, and are difficult to resist or control. 8 The condition causes impaired functioning in relationships, socializing, and intimacy, as well as a decreased ability to function at work, in school, or in other daily activities. 4, 9 Anxiety disorders, depression, and eating disorders frequently co-occur with BDD, and the disorder is associated with significant suicidality. [10] [11] [12] The onset of BDD commonly occurs during adolescence;
however, patients are generally diagnosed 10-15 years later. 11, 13 BDD patients generally feel misunderstood and are secretive about their symptoms because they think they will be viewed as vain or narcissistic. Moreover, most BDD patients have poor insight into their illness; 30 to 60% of patients are even delusional regarding their perceived appearance flaws, and they do not recognize a need for psychological or psychiatric treatment. 14 As the skin is one of the most commonly reported areas of concern in BDD, many BDD sufferers seek dermatological or surgical treatment in an attempt to relieve their symptoms. 15, 16 However, BDD often goes unrecognized by dermatologists, plastic surgeons, and other physicians whom these patients approach first in their attempts to correct their perceived flaws. 12, 20 Body dysmorphic disorder prevalence rates of 1.7-2.4% have been identified in general population samples in Germany, Sweden, and the United States. [21] [22] [23] [24] In dermatology settings, a few studies have systematically assessed the occurrence of BDD and have found higher prevalence rates of 4.5-14%. [25] [26] [27] [28] [29] [30] [31] [32] Some studies have reported lower prevalence rates among general dermatology patients (2.1-6.7%) than among cosmetic dermatology patients (7.5-14%). [29] [30] [31] In summary, BDD patients attending dermatology clinics may be at risk of not receiving an appropriate assessment and beneficial treatment. Because there are no known data on BDD occurrence in clinical settings in Sweden, the primary aim of this study was to use a validated questionnaire to estimate the BDD prevalence rate among Swedish female dermatology patients.
Women were chosen because the questionnaire had previously been validated in Swedish women. To estimate the psychological condition of BDD patients compared to that of other dermatology patients, the secondary aims were to study the co-occurrence of depression and anxiety, assess quality of life, and investigate BDD patients' reasons for seeking dermatologic care.
Method
Participants From February to September 2013, 523 patients were consecutively enrolled at two tertiary care dermatologic outpatient clinics in Sweden. The eligibility criteria included female noncancer, general dermatology patients aged 18-60 years. Validated selfscreening instruments were used to assess the prevalence of BDD, symptoms of depression and anxiety, and quality of life. A total of 425 women participated in the study after excluding seven responders because of nonresponse on items required for BDD diagnosis. Thus, the response rate was 81%. The study was approved by the Regional Ethics Board, Link€ oping, Sweden.
Measurements
The Body Dysmorphic Disorder Questionnaire (BDDQ) is a brief, self-report measure that is derived from the DSM-IV diagnostic criteria for BDD (Fig. 1) . The questionnaire was developed as a screening instrument for BDD and has exhibited high sensitivity (100%) and specificity (89-93%) when validated in psychiatric samples. 33, 34 The BDDQ has also been validated against the Structured Clinical Interview for DSM-IV (SCID) in a subsample (n = 127) of a facial cosmetic surgery sample and displayed a sensitivity of 100% and a specificity of 91%. 35 The BDDQ dermatology version, a modification of the BDDQ with continuous scoring on items evaluating distress and impairment, was validated in dermatology patients seeking cosmetic surgical consultation, and presented high sensitivity and specificity (100% and 92%, respectively). 36 The Swedish translation of the BDDQ has been validated against face-to-face diagnostic interviews using the SCID in a community sample of Swedish women and exhibited a sensitivity of 94% and a specificity of 90%. 37 The original intention was to complement a positive BDDQ screening with a diagnostic interview using the SCID and a dermatological evaluation of the perceived appearance 
Statistical methods
The reliability of the HADS and DLQI scales was estimated by calculating Cronbach's alpha. Sociodemographics and HADS and DLQI scores were compared between patients with a positive and negative BDD screening (BDD/no BDD). Betweengroup differences in sociodemographics were assessed using The adjusted ORs were assessed after adjusting for age. Effect sizes for the differences in DLQI scores were estimated by the product-moment correlation coefficient r, calculated from the Zscore obtained by the Mann-Whitney U tests, 43 and were interpreted as outlined by Cohen, 44 0.1 = small effect, 0.3 = medium effect, and 0.5 = large effect. All analyses were performed using IBM SPSS Statistics version 22.0 software. The level of statistical significance was set at P < 0.05.
Results

Prevalence of BDD
The results of the BDDQ are presented in Figure 1 . Almost half of the respondents (46%) reported being very concerned about some parts of their body that they considered especially unattractive, and 33% reported being preoccupied by these concerns. Approximately half of the patients with a preoccupation with appearance concerns had primary concerns of not being thin enough or feared becoming fat and were excluded from further BDD assessment. In total, 4.9% (95% CI 3.2-7.4) of the patients screened positive for BDD.
The patients with positive BDD screening were younger, with a mean age of 31 years, compared to 40 years in patients without BDD (P = 0.001) ( The body areas that the patients who screened positive for BDD reported that they were preoccupied with, together with the patients' reasons for attending the clinic, are presented in Table 2 . For some patients, their reasons for attending the clinic were presumably to seek treatment for their perceived appearance flaw (e.g. seeking treatment for acne when preoccupied with the facial skin). However, not all patients sought dermatologic care because of their reported appearance preoccupations, and, for some patients, it was not obvious whether their preoccupation was the reason for attending the clinic.
Depression, anxiety, and quality of life Depression (HADS D ≥ 11) was reported by 2.7%, and anxiety (HADS A ≥ 11) was reported by 13.2% of the total sample. Depression was over 10-fold more common in patients with positive BDD screening (19% vs. 1.8%) (P < 0.001), and anxiety was four-fold more common in patients with positive BDD screening (48% vs. 11%) (P < 0.001) ( Table 3 ). The median total DLQI score was 18 in the BDD group, compared to 4 in the non-BDD group (P < 0.001) ( Table 3 ). The interpretation of the DLQI scores with regard to the effect on the patients' lives is illustrated in Figure 2 , indicating that quality of life was significantly more affected in patients with positive BDD screening (adjusted OR 10.5 [95% CI 4.5-4.8], P < 0.001). All DLQI subdomains were significantly more affected in patients with positive BDD screening.
Discussion
We identified a BDD prevalence of 4.9% (95% CI 3.2-7.4) among female Swedish dermatology patients (n = 425), as estimated using the BDDQ. These results confirm earlier research reporting that BDD is fairly common in dermatology settings and indicate that BDD is more than twice as common in dermatology patients than in the general population of Swedish women (2.1%). 23 The BDD prevalence rate found in our sample was lower than that in some previous studies of general dermatology 30, 31 In our study, we used an instrument with good Of the total patients, 416 completed HADS-A, 408 completed HADS-D, and 423 completed the DLQI (all nonresponders were in the non-BDD group and these individuals were excluded from the analyses). r = product-moment correlation r estimated from the Mann-Whitney U test; 0.10 = small effect, 0.30 = medium effect, and 0.50 = large effect. HADS, Hospital Anxiety and Depression Scale; DLQI, Dermatology Life Quality Index. Mean scores for each of the six subdomains composing the DLQI expressed as a percentage of the maximum subdomain score (3 or 6).
c OR = Odds ratio (95% confidence interval), adjusted for age.
validity, that excludes patients with primary weight concerns to avoid overdiagnosing BDD when an eating disorder may be a more accurate diagnosis. 45 However, eating disorders and BDD can be comorbid conditions, in which case both disorders should be diagnosed. 46 Therefore, screening for BDD using the To the best of our knowledge, no previous studies have reported data on the psychological condition of BDD patients in dermatology settings. The high levels of depression and anxiety in patients who screened positive for BDD in our study support the findings of previous studies of BDD patients. In the largest samples of BDD patients, the lifetime prevalence of major depression, as assessed by the SCID, was 75-76%, and the current prevalence was 58%. 10, 11 In those studies, the lifetime prevalence of anxiety disorders (most commonly social anxiety disorder) was 64-73%, and the current prevalence was 55%. Studies using the screening questionnaire Montgomery and Asberg Depression Scale (MADRS) have reported depression in 28-50% of BDD patients (defined as a score of >20 to denote clinically significant depression). 47, 48 The rates of depression (19%) and anxiety (48%) found in BDD patients in this study were thus lower than those in previous studies, although the rates are difficult to compare owing to differences in assessment methods. In the total sample, we found depression in 2.7% and anxiety in 13.2% of the dermatology patients, which were lower rates compared with results from a large European multicenter study of dermatological outpatients (n = 3635) that reported depression in 10% and anxiety in 17% of the patients based on a HADS cut-off score of 11. 49 Although other Scandinavian countries were included, Sweden was not represented in the multicenter study, and existing data from Sweden are limited. Therefore, more studies are needed to compare the psychological condition of BDD patients with that of other dermatology patients.
Quality of life was severely impaired in the patients with positive BDD screening, with a median DLQI score of 18, which is compatible with very large effects on the patients' lives. There are no norm data for the DLQI; however, a mean total DLQI score of 0.5 for healthy controls and a mean score of 7.3 for dermatology patients has been reported. 41 As a comparison with scores for some of the dermatology disorders associated with considerably impaired quality of life, recent reviews have 52 In our study, the patients with positive BDD screening were also unemployed and on sick leave to a higher degree, findings that indicate potential consequences of the disorder.
In conclusion, this is the largest study assessing BDD prevalence in dermatology settings, and the results confirm that BDD seems to be fairly common among patients attending dermatology clinics. The patients who screened positive for BDD experienced symptoms of anxiety and depression to a high degree, and their quality of life was severely impaired. As outlined by Gupta and Gupta, 53 it is important to rule out body image pathologies before initiating dermatologic therapies because patients with BDD are often dissatisfied with treatment outcomes and because body image dissatisfaction is associated with increased morbidity, intentional self-injury, and suicide. Thus, even if visible dermatological symptoms are mild, it is important to assess the emotional consequences of the patients' symptoms. Phillips and Dufresne 54 recommended that BDD patients should be referred to mental health professionals for treatment and emphasized the need to provide BDD patients with psycho-education about the disorder, rather than dismissing their concerns as trivial, trying to reassure them that treatments are unnecessary, or trying various appearance-enhancing treatments. Because dermatologists may be the first or only healthcare professionals approached by BDD patients, an increased awareness of BDD among dermatologists is vital to ensure that these patients receive the appropriate care.
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